{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:20:23Z","timestamp":1783142423803,"version":"3.54.6"},"reference-count":20,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.26009","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:11:02Z","timestamp":1782598262000},"page":"182-188","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment outcomes of peripheral T-cell lymphoma in the era of molecular targeted therapy"],"prefix":"10.3960","volume":"66","author":[{"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Maehara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitohiro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kusaba","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Kouseiren Tsurumi Hospital, Beppu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Chihara D, Ito H, Matsuda T <i>et al.<\/i> Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014; 164: 536-545.","DOI":"10.1111\/bjh.12659"},{"key":"2","unstructured":"2 Dogan A, Gaulard P, Jaffe ES, Muller-Hermelink HK, de Leval L (eds): Mature T- and NK-cell neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC. 2017; pp. 407-412."},{"key":"3","unstructured":"3 Attygalle AD, Alaggio R, Du MQ (eds): T-cell and NK-cell lymphoid proliferations and lymphomas. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th ed, Lyon, IARC. 2024; pp. 742-743."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Horwitz S, O\u2019Connor OA, Pro B <i>et al.<\/i> Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019; 393: 229-240.","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Bellei M, Foss FM, Shustov AR <i>et al.<\/i> The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018; 103: 1191-1197.","DOI":"10.3324\/haematol.2017.186577"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Ogura M, Ishida T, Hatake K <i>et al.<\/i> Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014; 32: 1157-1163.","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Horwitz SM, Advani RH, Bartlett NL <i>et al.<\/i> Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123: 3095-3100.","DOI":"10.1182\/blood-2013-12-542142"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Coiffier B, Pro B, Prince HM <i>et al.<\/i> Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7: 11.","DOI":"10.1186\/1756-8722-7-11"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Shojaei F, Goodenow B, Lee G, Kabbinavar F, Gillings M. HBI-8000, HUYABIO Lead Clinical Program, is a selective histone deacetylase inhibitor with therapeutic benefits in leukemia and in solid tumors. Front Oncol. 2022; 11: 768685.","DOI":"10.3389\/fonc.2021.768685"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Horwitz SM, Izutsu K, Mehta-Shah N <i>et al.<\/i> Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: primary results of the phase 2 VALENTINE-PTCL01 Study. Blood. 2023; 142: 302.","DOI":"10.1182\/blood-2023-179304"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 O\u2019Connor OA, Pro B, Pinter-Brown L <i>et al.<\/i> Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182-1189.","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Maruyama D, Tsukasaki K, Uchida T <i>et al.<\/i> Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T-cell lymphoma. Ann Hematol. 2019; 98: 131-142.","DOI":"10.1007\/s00277-018-3418-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ishida T, Fujiwara H, Nosaka K <i>et al.<\/i> Multicenter Phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016; 34: 4086-4093.","DOI":"10.1200\/JCO.2016.67.7732"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kawai H, Ando K, Maruyama D <i>et al.<\/i> Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021; 112: 2426-2435.","DOI":"10.1111\/cas.14906"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kim WS, Fukuhara N, Yoon DH <i>et al.<\/i> Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study. Blood Adv. 2023; 7: 4903-4912.","DOI":"10.1182\/bloodadvances.2022008615"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Bachy E, Camus V, Thieblemont C <i>et al.<\/i> Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP Phase III Study (conducted by LYSA). J Clin Oncol. 2022; 40: 242-251.","DOI":"10.1200\/JCO.21.01815"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ruan J, Moskowitz A, Mehta-Shah N <i>et al.<\/i> Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023; 141: 2194-2205.","DOI":"10.1182\/blood.2022018254"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Lemonnier F, Safar V, Beldi-Ferchiou A <i>et al.<\/i> Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021; 5: 539-548.","DOI":"10.1182\/bloodadvances.2020003081"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/2\/66_26009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:14:16Z","timestamp":1783142056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/2\/66_26009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.26009","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"26009"}}